Eikon Therapeutics, Inc.
EIKNEikon Therapeutics, Inc. in brief
Eikon Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Millbrae, California, USA. Its market value was $290 M on 30 October 2026, which makes it the 14,928th largest listed company in the world and the 2,908th largest in the USA on this site. It employs about 384 people. Its shares trade under the symbol EIKN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Eikon Therapeutics, Inc.
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.
From the company's annual report filed with the US SEC: read the report
Eikon Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 5 February 2026; shares registered for exchange trading on 28 January 2026.
Events of Eikon Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,426 (Aug 2026) · #2,912 (Oct 2026)
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-86M.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 26, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 23, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 14, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 3, 20268-KCurrent reportDirectors or officers changed
- Jun 10, 20268-KCurrent reportDirectors or officers changed
- Jun 1, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Eikon Therapeutics, Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $595 M
- Total liabilities
- $312 M
- Total equity
- $-879 M
As of December-2025
Top 98 institutional investors in Eikon Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5,520,152 | +526,246 (+10.54%) | 10.19% | $44 M | Nov 10, 2026 |
| 2 | BlackRock, Inc. | 4,869,276 | +587,851 (+13.73%) | 8.99% | $39 M | Nov 13, 2026 |
| 3 | Foresite Capital Management IV, LLC | 1,943,682 | 0 (0.00%) | 3.59% | $16 M | Nov 16, 2026 |
| 4 | Merck & Co., Inc. | 1,666,666 | 0 (0.00%) | 3.08% | $13 M | Nov 13, 2026 |
| 5 | T. Rowe Price Investment Management, Inc. | 1,637,441 | +42,167 (+2.64%) | 3.02% | $13 M | Nov 16, 2026 |
| 6 | Foresite Capital Management V, LLC | 1,318,983 | 0 (0.00%) | 2.43% | $11 M | Nov 16, 2026 |
| 7 | Capital World Investors | 1,175,944 | 0 (0.00%) | 2.17% | $9 M | Nov 12, 2026 |
| 8 | Price T Rowe Associates Inc /MD/ | 1,110,649 | +105,614 (+10.51%) | 2.05% | $9 M | Nov 16, 2026 |
| 9 | Alliancebernstein L.P. | 1,052,041 | +410,153 (+63.90%) | 1.94% | $8 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 1,015,513 | +92,806 (+10.06%) | 1.87% | $8 M | Nov 13, 2026 |
| 11 | EcoR1 Capital, LLC | 855,634 | +123,028 (+16.79%) | 1.58% | $7 M | Nov 16, 2026 |
| 12 | Geode Capital Management, LLC | 754,499 | +197,544 (+35.47%) | 1.39% | $6 M | Nov 6, 2026 |
| 13 | Regents Of The University Of California | 635,131 | New | 1.17% | $5 M | Oct 26, 2026 |
| 14 | State Street Corp | 608,838 | +254,745 (+71.94%) | 1.12% | $5 M | Nov 12, 2026 |
| 15 | Baker Bros. Advisors LP | 555,555 | 0 (0.00%) | 1.03% | $4 M | Nov 16, 2026 |
| 16 | StepStone Group LP | 523,467 | +128,127 (+32.41%) | 0.97% | $4 M | Nov 17, 2026 |
| 17 | Soros Capital Management LLC | 484,672 | 0 (0.00%) | 0.89% | $4 M | Nov 13, 2026 |
| 18 | Millennium Management LLC | 419,095 | +286,075 (+215.06%) | 0.77% | $3 M | Nov 16, 2026 |
| 19 | Walleye Capital LLC | 391,273 | New | 0.72% | $3 M | Nov 13, 2026 |
| 20 | Canada Pension Plan Investment Board | 379,024 | 0 (0.00%) | 0.70% | $3 M | Nov 16, 2026 |
| 21 | Citadel Advisors LLC | 354,016 | +340,993 (+2618.39%) | 0.65% | $3 M | Nov 16, 2026 |
| 22 | Franklin Templeton Inc | 350,000 | 0 (0.00%) | 0.65% | $3 M | Nov 12, 2026 |
| 23 | Affinity Asset Advisors, LLC | 298,001 | +200,000 (+204.08%) | 0.55% | $2 M | Nov 13, 2026 |
| 24 | UBS Group AG | 278,904 | +14,972 (+5.67%) | 0.51% | $2 M | Nov 10, 2026 |
| 25 | Charles Schwab Investment Management Inc | 259,531 | +77,426 (+42.52%) | 0.48% | $2 M | Nov 16, 2026 |
Show all 98: investors 26 to 98
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Morgan Stanley | 247,112 | +235,080 (+1953.79%) | 0.46% | $2 M | Nov 13, 2026 |
| 27 | Northern Trust Corp | 246,016 | +70,089 (+39.84%) | 0.45% | $2 M | Nov 16, 2026 |
| 28 | Vanguard Portfolio Management LLC | 223,019 | +74,124 (+49.78%) | 0.41% | $2 M | Nov 13, 2026 |
| 29 | Vanguard Fiduciary Trust Co | 202,239 | +53,829 (+36.27%) | 0.37% | $2 M | Nov 13, 2026 |
| 30 | Two Sigma Investments, LP | 184,198 | New | 0.34% | $1 M | Nov 16, 2026 |
| 31 | Woodline Partners LP | 162,254 | New | 0.30% | $1 M | Nov 16, 2026 |
| 32 | Ensign Peak Advisors, Inc | 142,498 | -27,992 (-16.42%) | 0.26% | $1 M | Nov 12, 2026 |
| 33 | Comprehensive Financial Management LLC | 140,856 | +24,580 (+21.14%) | 0.26% | $1 M | Nov 16, 2026 |
| 34 | Bank Of America Corp /de/ | 137,457 | +99,882 (+265.82%) | 0.25% | $1 M | Nov 16, 2026 |
| 35 | BNP Paribas Financial Markets | 137,415 | +128,906 (+1514.94%) | 0.25% | $1 M | Nov 12, 2026 |
| 36 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 134,498 | 0 (0.00%) | 0.25% | $1 M | Nov 13, 2026 |
| 37 | XTX Topco Ltd | 133,167 | +105,712 (+385.04%) | 0.25% | $1 M | Nov 16, 2026 |
| 38 | Goldman Sachs Group Inc | 127,887 | New | 0.24% | $1 M | Nov 16, 2026 |
| 39 | Alps Advisors Inc | 71,255 | +16,307 (+29.68%) | 0.13% | $1 M | Nov 3, 2026 |
| 40 | Bank of New York Mellon Corp | 65,871 | +18,083 (+37.84%) | 0.12% | $1 M | Nov 5, 2026 |
| 41 | Los Angeles Capital Management LLC | 63,830 | New | 0.12% | $1 M | Nov 12, 2026 |
| 42 | Aquatic Capital Management LLC | 62,883 | New | 0.12% | $1 M | Nov 16, 2026 |
| 43 | Jpmorgan Chase & Co | 56,951 | +46,627 (+451.64%) | 0.11% | $0 M | Nov 12, 2026 |
| 44 | AQR Capital Management LLC | 52,492 | New | 0.10% | $0 M | Nov 16, 2026 |
| 45 | Invesco Ltd. | 51,158 | +258 (+0.51%) | 0.09% | $0 M | Nov 12, 2026 |
| 46 | Trexquant Investment LP | 48,500 | New | 0.09% | $0 M | Nov 16, 2026 |
| 47 | EntryPoint Capital, LLC | 47,943 | New | 0.09% | $0 M | Nov 13, 2026 |
| 48 | Nuveen, LLC | 46,312 | +17,324 (+59.76%) | 0.09% | $0 M | Nov 10, 2026 |
| 49 | D. E. Shaw & Co., Inc. | 39,240 | New | 0.07% | $0 M | Nov 16, 2026 |
| 50 | TCG Crossover Management, LLC | 37,902 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 51 | DCF Advisers, LLC | 33,792 | New | 0.06% | $0 M | Nov 4, 2026 |
| 52 | Quadrature Capital Ltd | 28,399 | New | 0.05% | $0 M | Nov 13, 2026 |
| 53 | Rhumbline Advisers | 27,856 | +3,373 (+13.78%) | 0.05% | $0 M | Nov 10, 2026 |
| 54 | Deutsche Bank AG\ | 27,230 | +5,708 (+26.52%) | 0.05% | $0 M | Nov 6, 2026 |
| 55 | Y-Intercept (Hong Kong) Ltd | 20,297 | New | 0.04% | $0 M | Oct 16, 2026 |
| 56 | MetLife Investment Management, LLC | 19,235 | +5,480 (+39.84%) | 0.04% | $0 M | Nov 16, 2026 |
| 57 | ProShare Advisors LLC | 15,757 | -13,928 (-46.92%) | 0.03% | $0 M | Oct 29, 2026 |
| 58 | Entropy Technologies, LP | 15,500 | New | 0.03% | $0 M | Nov 13, 2026 |
| 59 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 15,320 | +5,339 (+53.49%) | 0.03% | $0 M | Nov 16, 2026 |
| 60 | Tudor Investment Corp Et Al | 15,000 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 61 | Prelude Capital Management, LLC | 13,066 | New | 0.02% | $0 M | Nov 16, 2026 |
| 62 | Squarepoint Ops LLC | 13,026 | New | 0.02% | $0 M | Nov 9, 2026 |
| 63 | Barclays PLC | 12,462 | +7,827 (+168.87%) | 0.02% | $0 M | Nov 6, 2026 |
| 64 | Vanguard Global Advisers, LLC | 11,991 | +3,507 (+41.34%) | 0.02% | $0 M | Nov 13, 2026 |
| 65 | Integrated Wealth Concepts LLC | 10,946 | +46 (+0.42%) | 0.02% | $0 M | Nov 17, 2026 |
| 66 | Osaic Holdings, Inc. | 10,535 | +10,000 (+1869.16%) | 0.02% | $0 M | Nov 12, 2026 |
| 67 | Jump Financial, LLC | 10,400 | -7,669 (-42.44%) | 0.02% | $0 M | Nov 13, 2026 |
| 68 | Creative Planning | 10,177 | New | 0.02% | $0 M | Nov 2, 2026 |
| 69 | Pavaki Capital Management LLC | 10,000 | New | 0.02% | $0 M | Oct 26, 2026 |
| 70 | Police & Firemen's Retirement System of New Jersey | 8,974 | +2,554 (+39.78%) | 0.02% | $0 M | Nov 9, 2026 |
| 71 | Wells Fargo & Company/mn | 8,640 | -10,708 (-55.34%) | 0.02% | $0 M | Nov 16, 2026 |
| 72 | New York State Common Retirement Fund | 6,200 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 73 | Royal Bank Of Canada | 3,555 | +771 (+27.69%) | 0.01% | $0 M | Nov 16, 2026 |
| 74 | Legal & General Group Plc | 2,967 | +849 (+40.08%) | 0.01% | $0 M | Nov 16, 2026 |
| 75 | Ameritas Investment Partners, Inc. | 2,855 | +880 (+44.56%) | 0.01% | $0 M | Nov 13, 2026 |
| 76 | Russell Investments Group, Ltd. | 1,837 | +97 (+5.57%) | 0.00% | $0 M | Nov 6, 2026 |
| 77 | Citigroup Inc | 1,573 | -15,206 (-90.63%) | 0.00% | $0 M | Nov 4, 2026 |
| 78 | Tower Research Capital LLC (TRC) | 1,308 | -2,327 (-64.02%) | 0.00% | $0 M | Nov 16, 2026 |
| 79 | Arax Advisory Partners | 1,208 | New | 0.00% | $0 M | Nov 12, 2026 |
| 80 | IFP Advisors, Inc | 969 | +51 (+5.56%) | 0.00% | $0 M | Oct 16, 2026 |
| 81 | Sterling Capital Management LLC | 921 | +731 (+384.74%) | 0.00% | $0 M | Oct 22, 2026 |
| 82 | Allworth Financial LP | 594 | +94 (+18.80%) | 0.00% | $0 M | Nov 17, 2026 |
| 83 | State of Wyoming | 363 | -186 (-33.88%) | 0.00% | $0 M | Oct 28, 2026 |
| 84 | California State Teachers Retirement System | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 85 | Global Retirement Partners, LLC | 252 | New | 0.00% | $0 M | Nov 10, 2026 |
| 86 | Farther Finance Advisors, LLC | 149 | New | 0.00% | $0 M | Oct 8, 2026 |
| 87 | Aspect Partners, LLC | 140 | +14 (+11.11%) | 0.00% | $0 M | Oct 20, 2026 |
| 88 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 130 | New | 0.00% | $0 M | Nov 16, 2026 |
| 89 | GAMMA Investing LLC | 128 | New | 0.00% | $0 M | Oct 8, 2026 |
| 90 | Fortitude Family Office, LLC | 121 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 91 | EverSource Wealth Advisors, LLC | 95 | New | 0.00% | $0 M | Nov 4, 2026 |
| 92 | True Wealth Design, LLC | 45 | New | 0.00% | $0 M | Oct 13, 2026 |
| 93 | Caitong International Asset Management Co., Ltd | 17 | +13 (+325.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 94 | Essential Partners LLC | 15 | New | 0.00% | $0 M | Oct 14, 2026 |
| 95 | Clearstead Advisors, LLC | 10 | New | 0.00% | $0 M | Nov 6, 2026 |
| 96 | Rothschild Investment LLC | 7 | New | 0.00% | $0 M | Nov 10, 2026 |
| 97 | SJS Investment Consulting Inc. | 6 | New | 0.00% | $0 M | Oct 26, 2026 |
| 98 | SBI Securities Co., Ltd. | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Eikon Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC | 1.28 M | $17 M | 2.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc | 1.14 M | $15 M | 2.1% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 926,046 | $12 M | 1.7% | 0.11% | +29% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 974,333 | $11 M | 1.8% | 0.20% | +219% | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 660,117 | $9 M | 1.2% | <0.01% | −7.3% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 722,389 | $8 M | 1.3% | 0.13% | no change | May 29, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 510,661 | $7 M | 0.94% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 602,300 | $7 M | 1.1% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 349,098 | $5 M | 0.64% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 331,011 | $4 M | 0.61% | 0.03% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC | 265,469 | $3 M | 0.49% | <0.01% | −1.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 235,174 | $3 M | 0.43% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 237,756 | $2 M | 0.44% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 140,757 | $2 M | 0.26% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 169,228 | $2 M | 0.31% | <0.01% | +37% | May 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 154,400 | $2 M | 0.28% | <0.01% | +38% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 121,628 | $2 M | 0.22% | 0.15% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 140,013 | $1 M | 0.26% | 0.05% | +0.8% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 109,803 | $1 M | 0.20% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 127,376 | $1 M | 0.24% | 0.10% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 99,752 | $1 M | 0.18% | <0.01% | new | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 72,988 | $1 M | 0.13% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 70,430 | $1 M | 0.13% | 0.11% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 63,966 | $1 M | 0.12% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 63,218 | $1 M | 0.12% | 0.14% | no change | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 43,100 | $1 M | 0.08% | 0.15% | no change | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 40,689 | $1 M | 0.08% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 52,895 | $0 M | 0.10% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 44,280 | $0 M | 0.08% | <0.01% | new | May 31, 2026 |
| 🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P. | 35,180 | $0 M | 0.06% | 0.01% | −93% | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World FundCapital Research and Management Company | 32,307 | $0 M | 0.06% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 32,257 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 30,772 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC | 23,796 | $0 M | 0.04% | 0.10% | −2.3% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 22,893 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 20,976 | $0 M | 0.04% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 28,988 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 16,200 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 14,003 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 15,556 | $0 M | 0.03% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 11,999 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 11,243 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 14,000 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 11,872 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 9,499 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 9,490 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 7,797 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 7,439 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 10,357 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 7,211 | $0 M | 0.01% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC | 6,500 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 6,108 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 5,800 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 5,071 | $0 M | <0.01% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,880 | $0 M | <0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,748 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 4,733 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,408 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,321 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,212 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,902 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,680 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,680 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,606 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,216 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,923 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,975 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,549 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,740 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,611 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,337 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,893 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC | 1,300 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,042 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,031 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 1,156 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 908 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,276 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Guardian Large Cap Fundamental Growth VIP FundPark Avenue Institutional Advisers LLC | 900 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 755 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 549 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 428 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 510 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 367 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 245 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 218 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 86 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Eikon Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Tim Kutzkey10% owner | Buyindirect | +89,200 | $11.56 | $1.0 M | 89,200 | Form 4 |
| filed | Roger M. PerlmutterSee remarks, Director | Conversionindirect | +284,857 | — | — | 284,857 | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +1.30 M | — | — | 1.36 M | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +1.40 M | — | — | 2.76 M | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +110,928 | — | — | 2.87 M | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +44,249 | — | — | 47,601 | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +47,898 | — | — | 95,499 | Form 4 |
| filed | Column Group Opportunity III, LP10% owner | Conversionindirect | +3,785 | — | — | 99,284 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Eikon Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $18.00, raising $381.2M · IPO calendar
Fails to deliver
- : 18 shares at $5.35
- : 8,909 shares at $5.55
- : 175 shares at $5.54
- : 1,428 shares at $8.18
- : 222 shares at $7.33
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Eikon Therapeutics, Inc. scorecard#
Passes 1 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 1
- –P/E below its peers' medianNo P/E on file.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- –Earnings yield above the 10-year Treasury yieldNo P/E on file.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 1
- ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.34 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Eikon Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Bylaws or fiscal year changed 1 · Results announced 4
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2025 | $351 M | No. 4 | $250 million to $1 billion | 27 | equity, options | SEC |
| May 2023 | $141 M | No. 3 | $50 to $250 million | 21 | equity | SEC |
| Dec 2021 | $518 M | No. 2 | $250 million to $1 billion | 43 | equity | SEC |
| May 2021 | $103 M | No. 1 | $50 to $250 million | 12 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Eikon Therapeutics, Inc.#
19 labor condition applications certified in fiscal 2026 for 19 positions, at a median wage of $144 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Biologist (Sr. Research Associate)Molecular and Cellular Biologists | 2 | $113 K |
| Assoc. Dir., Clinical Study ManagementClinical Research Coordinators | 1 | $184 K |
| Associate Director, Clinical Data Analytics and ReportingData Scientists | 1 | $207 K |
| Clinical Trial Mgmt AssocClinical Research Coordinators | 1 | $107 K |
| Engineer, SoftwareSoftware Developers | 1 | $130 K |
| Lab Data ManagerClinical Data Managers | 1 | $109 K |
| Lead Veeva Vault AdminComputer Systems Analysts | 1 | $149 K |
| Manager, Clin Trial Master File AdminClinical Data Managers | 1 | $140 K |
| Manager, Regulatory Submission PublisherRegulatory Affairs Managers | 1 | $105 K |
| Manager, Software EngineeringComputer and Information Systems Managers | 1 | $183 K |
Where: Jersey City, NJ 9 · Millbrae, CA 7 · Los Angeles, CA 1 · Portland, OR 1 · Hayward, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 19 | 19 | $144 K | 19 |
| FY2025 | 13 | 13 | $153 K | 13 |
| FY2024 | 19 | 19 | $138 K | 19 |
| FY2023 | 8 | 8 | $146 K | 8 |
| FY2022 | 3 | 3 | $156 K | 3 |
| FY2021 | 2 | 2 | $178 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Eikon Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | 55 | · | · | · | · | · | · | · | 55 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 55 people | LayoffWARN notice | Millbrae, California | Notice list |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Eikon Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Eikon Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $86 million.
- Mutual funds: 86 funds hold $124 millionautomatic update · Jul 31, 2026
86 mutual funds in 1 country hold shares of Eikon Therapeutics, Inc. worth $124 million, about 18.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 59 funds added shares and 9 sold; on balance they bought $25 million. Share splits are not counted as trading.
How Eikon Therapeutics, Inc. compares in Biotechnology
- Market cap$290 M · higher than 50% of 726
- 🇺🇸 Agenus Inc.$290 M
- 🇺🇸 SAB Biotherapeutics, Inc.$291 M
- 🇺🇸 Alector, Inc.$293 M
- 🇺🇸 Vogenx, Inc.$296 M
- 🇮🇪 Amarin Corporation$297 M
- 🇺🇸 Fulcrum Therapeutics, Inc.$283 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Eikon Therapeutics, Inc.🇺🇸 | $290 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Eikon Therapeutics, Inc.? Verify and update this profile — free
Show Eikon Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.